×
返回 Agenda
Session 6 Track 2: Mind Over Matter: Cracking the Code of CNS Delivery
Session Chair(s)
Aimee L. Jackson, PHD
, Miragen Therapeutics, United States
Considerations for the distribution and safety of oligonucleotide therapeutics for CNS applications.
Learning Objective : - Compare the distribution and safety profiles of oligos delivered systemically or directly into the CSF
- Identify the opportunities and challenges of different approaches to delivering oligonucleotides to the brain; when does systemic administration for BBB transit make sense and when is local administration the better choice?
- Apply stability, PK/PD, and safety information to identify the optimal approaches to targeting brain diseases
Speaker(s)
Representative Invited
Director, Toxicology, Denali Therapeutics, United States
Speaker
Representative Invited
Toxicologist, Ionis Pharmaceuticals, Inc., United States
Speaker